The latest in the deals landscape in China has seen Wenzhou Kangninzg is exploring a secondary listing on the Shanghai bourse, while Rici Healthcare is reviving its Hong Kong IPO plans, even as the trade sale of Golden Meditechs stake in China Cord Blood Corporation is under threat.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
